#ASH22: Lil­ly’s Loxo rounds out the PhI/II da­ta for lym­phoma drug un­der FDA re­view

NEW OR­LEANS — Fol­low­ing up on two sub­sets pre­sent­ed Sat­ur­day, Eli Lil­ly’s Loxo On­col­o­gy fleshed out the da­ta on its non-co­va­lent BTK in­hibitor pir­to­bru­ti­nib in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER